

PTO 892 DEAFCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NOTICE OF REFERENCES CITED	SERIAL NUMBER 08/854,825	Art Unit 1648	Attachment to Paper Number
			5

APPLICANT(S) :Chisari <i>et al.</i>

U.S. PATENT DOCUMENTS


*	DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	PERTINENT DRW SPEC

OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Smith <i>et al.</i> , 1997, "Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing," Intl. Immunol. 9(8):1085-1093.
	Nayersina <i>et al.</i> , 1993, "HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection," J. Immunol. 150(10):4659-4671.
	Bertoletti <i>et al.</i> , 1994, "Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope," J. Exp. Med. 180:933-943.
	Johnson <i>et al.</i> , 1992, "Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation," J. Exp. Med. 175:961-971.
*	Del Val <i>et al.</i> , 1991, "Efficient processing of an antigenic sequence for presentation by MCH class I molecules depends on its neighboring residues in the protein," Cell 66:1145-1153.
	Rehmann <i>et al.</i> , 1996, "Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection," J. Clin. Invest. 98(6):1432-1440.
	Lewin, R., 1987, "When does homology mean something else?," Science 237:1570.
	Reeck <i>et al.</i> , 1987, "Homology" in proteins and nucleic acids: a terminology muddle and a way out of it," Cell 50:667.

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE 02/23/98	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).) PAGE 1 OF 2
---	----------------------	---

PTO 892 DEAFCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE NOTICE OF REFERENCES CITED	SERIAL NUMBER 08/854,825	Art Unit 1648	Attachment to Paper Number
			5

APPLICANT(S) : Chisari <i>et al.</i>

U.S. PATENT DOCUMENTS


*	DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	PERTINENT DRW SPEC

*	OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
---	---

*	Hahn <i>et al.</i> , 1992, "CD8* T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope," J. Exp. Med. 176:1335-1341.
*	Hansen <i>et al.</i> , 1993, " The Major Histocompatibility Complex," in <i>Fundamental Immunology</i> , Paul, ed., Raven Press, New York, NY, pp. 577-628.
*	Koziel <i>et al.</i> , 1993, "Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV," J. Virol. 67(12):7522-7532.
*	Monaco, J., 1992, "A molecular model of MHC class-I-restricted antigen processing," Immunol. Today 13(5):173-179.
	Koziel <i>et al.</i> , 1997, "Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection," Springer Semin. Immunopathol. 19:69-83.
*	Koff, R., 1993, "A redoubtable obstacle to a hepatitis C vaccine," Gastroenterol. 104(4):1228-1229.
*	Prince, A., 1994, "Challenges for development of hepatitis C virus vaccines," FEMS Microbiol. Rev. 14:273-278.
	Boswell <i>et al.</i> , 1988, "Sequence comparison and alignment: the measurement and interpretation of sequence similarity," in <i>Computational Molecular Biology: Sources and Methods for Sequence Analysis</i> , Lesk, A., ed., Oxford University Press, New York, pp. 161-178.

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE 02/23/98	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a)). PAGE 2 OF 2
---	----------------------	--